anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study investigated the neurodevelopmental impact of pathogenic adenomatous polyposis coli (APC) gene variants in patients with familial adenomatous polyposis (FAP), a cancer predisposition syndrome. We hypothesized that certain pathogenic APC variants result in behavioral-cognitive challenges. We compared 66 FAP patients (cases) and 34 unaffected siblings (controls) to explore associations between APC variants and behavioral and cognitive challenges. Our findings indicate that FAP patients exhibited higher Social Responsiveness Scale (SRS) scores, suggesting a greater prevalence of autistic traits when compared to unaffected siblings (mean 53.8 vs. 47.4, Wilcoxon p = 0.018). The distribution of SRS scores in cases suggested a bimodal pattern, potentially linked to the location of the APC variant, with scores increasing from the 5' to 3' end of the gene (Pearson's r = 0.33, p = 0.022). While we observed a trend toward lower educational attainment in cases, this difference was not statistically significant. This study is the first to explore the connection between APC variant location and neurodevelopmental traits in FAP, expanding our understanding of the genotype-phenotype correlation. Our results emphasize the importance of clinical assessment for autistic traits in FAP patients, shedding light on the potential role of APC gene variants in these behavioral and cognitive challenges.
Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.
The invention discloses ternary composite asymmetric nanoparticles, and a preparation method and application thereof. Belongs to the field of nanometer materials. The composite nanomaterial takes a gold nano bipyramid as a substrate, and spherical silver-palladium alloy selectively grows at one end of the gold nano bipyramid. The other tip is not wrapped with anything and is shaped like a dart. The preparation method of the ternary nanoparticle combines the galvanic substitution reaction, the co-reduction reaction and the Oswald ripening effect. The Au-AgPd ternary composite asymmetric nanoparticle has the advantages of diversified physical and chemical properties, high purity and strong controllability. The Au-AgPd nanoparticle has three characteristics: excellent near infrared two-region photo-thermal conversion performance; can effectively catalyze hydrogen peroxide to generate active oxygen free radicals; one end of the exposed gold nano bipyramid is easy to load various functional molecules. The unique properties of the three-point Au-AgPd nanoparticle enable the three-point Au-AgPd nanoparticle to be used for near infrared two-region photo-thermal-catalytic combined treatment of tumor cells.
Example systems and methods provide anatomy map-based navigation and review of current and historical images and associated evidence. A method for navigating current and reference images and associated evidence includes loading a current image and a reference image for review via a navigator interface based on a time entry selection by a user. One or more markers indicating clinical findings or evidence are registered with at least one of the current image and the reference image. The one or more markers are displayed in conjunction with the current image and the reference image. A synopsis of information associated with a selected marker is provided upon selection of the marker by a user. A user can navigate through image and marker data over time by selecting each of a plurality of time entries to display images and associated markers for user review.
Medical imaging systems and methods are provided herein that provide for navigation and procedure planning without segmentation. A method comprises receiving, by a medical imaging system having at least one processing device, three-dimensional image data of a patient anatomy. The method also comprises filtering the three-dimensional data to display a portion of the three-dimensional image data that is associated with the patient anatomy and receiving, at the processing device, input from an operator input device. The input comprises navigational directions for virtual movement within a space defined by the three-dimensional image data. The method also includes tracking the virtual movement, defining a tracked pathway based on the tracked virtual movement, and generating a model of the patient anatomy based on the tracked pathway. The model of the patient anatomy is a line model including one or more lines based on the tracked pathway.
This study is designed as a single-center, single-dose, open-label study of the absorption, metabolism, and excretion of paliperidone in healthy men (3 extensive and 3 poor metabolizers based on CYP2D6 phenotype). Eligible volunteers will be admitted to the study center the evening before study drug administration and will remain at the study center until 168 hours after dosing (or longer if required up to a maximum of 14 days). Each volunteer will receive a single oral dose of 14C-paliperidone with total radioactivity below 1000 µSv (16 mCi). Blood samples for plasma pharmacokinetic profile will be obtained immediately before study drug administration and 0.5, 1, 1.5, 3, 6, 12, 16, 36, 48, 72, 96, 120, 144 and 168 hours postdose. Blood samples will be obtained 2, 4, 8 and 24 hours postdose for determination of 14C in whole blood. Samples for determination of serum creatinine will be obtained 2, 4, 8 and 24 hours postdose. Urine will be collected immediately prior to drug administration and from 0-4, 4-8, 8-12, 12-16, 16-24, 24-36, 36-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after study drug administration. Fecal samples will be collected per each stool, once before study drug administration and in the period from 0-168 hours after study drug administration. Collections of urine and feces (per 24 hours) will continue beyond 168 hours, to a maximum of 336 hours (Day 15) for patients who excrete radioactivity slowly (2 latest 24-hour urine collections each greater than or equal to 2% of total radioactive dose) or have \<7 feces stool samples over the 0 to 168-hour period. 14C radioactivity will be measured in plasma, urine, and feces. Aliquots of the 0- through 24 hour urine collections will be analyzed for creatinine. Plasma concentrations of paliperidone and risperidone will be determined by means of a validated LC MS/MS method. The 14C-labeled moiety in plasma and urine will be determined by liquid scintillation counting. For all plasma samples, the lower limits of quantification for paliperidone and risperidone will be 0.100 ng/mL. For all plasma and urine samples the lower limits of quantification for 14C-paliperidone will be 72 dpm/mL (=2.0n g eq/mL). The rationale for the present study with a single-dose administration of 1 mg 14C-paliperidone to healthy white men is to determine the routes of excretion for paliperidone and to elucidate the metabolic pathways and structures of predominant paliperidone metabolites. As such, this study will result in a more complete understanding of the pharmacokinetics of paliperidone in humans. Safety and tolerability will be monitored. Volunteers will receive a single oral 1 mg dose of 14C-paliperidone as a solution with a specific activity of 592 kBq/mg, resulting in an administered radioactivity of 592 kBq (or 16 µCi). The total radioactive load for the subject will remain lower than 1000 µSv.
Obstetric sepsis is a leading cause of maternal mortality and severe maternal morbidity in the United States. However, it is uncommon, and diagnosis and treatment are often delayed. This report summarizes recent work to develop a patient-centered approach for the care of patients with obstetric sepsis. To support patients, educational materials to identify warning signs paired with advocacy tips are important. Following an adverse event, outlines and checklists for patient support are provided. These tools have been developed to address a variety of obstetric conditions and have utility beyond sepsis. On the clinical side, new data to establish a standardized approach to screening and diagnosis is covered in detail. This "two-step" approach has been supported by national obstetric organizations and has similarities to the algorithm used to screen neonates for term early onset sepsis. In addition, the approach for implementation of a sepsis care bundle by the California/Michigan Obstetric Sepsis Quality Collaborative is discussed.
In the interventional group, another 42 patients with primary KOA will receive adipose tissue-derived mesenchymal stem cells (AT-MSCs) injection intra-articularly (Group-2). However, group-2 (Interventional group) will be subdivided into two sub-groups namely group-2a, and group-2b. A total of 21 Participants of group-2a will receive single doses of autologous adipose tissue-derived stem cell (AT-MSCs) and standard conservative care including rehabilitation for KOA. Whereas, group-2b, 21 respondents will receive two doses of autologous adipose tissue-derived stem cell (AT-MSCs) at 3 months intervals along with standard conservative care including rehabilitation for KOA.
The production method prepares a solid preparation by dissolving water-insoluble and/or water indissolvable alkaline active pharmaceutical ingredient in an acidifier-containing acid solution to obtain medicated acid liquid; homogeneously mixing alkalizer, adjuvants and the medicated acid liquid, and carrying out wet granulation. The alkalizer is a reagent to reduce the acidity of the mixture of the alkalizer and the medicated acid liquid relative to the acidity of the medicated acid liquid. The preparation method avoids the problems in mechanical pulverization, such as environmental pollution, great loss and serious security risks. This method is simply operated, has high safety coefficient and is convenient for industrialized production. Also disclosed is the solid preparation produced by the method. The solid preparation produced by the method has better dissolution performance than that produced by prior art, and has better or at least equivalent stability and content uniformity with prior art.
Initial assessments of participants were made before the first session. Using an elliptical bicycle or bicycle, or treadmill under the supervision of a physiotherapist, a total of 150 minutes moderate intensity (50-70% of maximal heart rate (HRmax)) aerobic exercise in accordance with the World Health Organization's guideline was applied, 3 days/week (50 mins/session) or 5 days/week (30 mins /session) for 4 weeks. The instruments to be used for the exercises were chosen according to the preference of the individual. HRmax was calculated using the "220-years". For example; at the age of 20 years, the target heart rate was determined as 100-140 beats/min for moderate physical activity in a person with HRmax 200 beats/min.
Paliperidone extended-release tablet contains paliperidone USP, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. Paliperidone contains a racemic mixture of (+)- and (-)- paliperidone. The chemical name is (±)-3-[2-[4-(6-fluoro-1,2-‑benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-‑pyrido[1,2-a]pyrimidin-4-one. Its molecular formula is C23H27FN4O3 and its molecular weight is 426.49. The structural formula is:

Paliperidone is sparingly soluble in 0.1N HCl and methylene chloride; practically insoluble in water, 0.1N NaOH, and hexane; and slightly soluble in N,N-dimethylformamide. 

Paliperidone extended-release tablets are intended for oral administration and are available in 1.5 mg (brown), 3 mg (white to off-white), 6 mg (yellow), and 9 mg (pink) strengths. Paliperidone extended-release tablets are formulated as a polymer matrix based once-a-day controlled release tablet for oral use.

Inactive ingredients are polyethylene oxide, hypromellose, anhydrous lactose, magnesium stearate, ethyl cellulose, triethyl citrate, talc, titanium dioxide and polyethylene glycol. The 1.5 mg and 6 mg tablets also contain lactose monohydrate, iron oxide yellow and iron oxide red. The 9 mg tablets also contain lactose monohydrate and iron oxide red.

Imprinting ink contains shellac glaze, iron oxide black, N-butyl alcohol, propylene glycol and ammonium hydroxide. 

Delivery System Components and Performance

Paliperidone extended release tablets employ a film-coated hydrophilic hydrogel matrix to deliver paliperidone at a controlled rate over 24 hours. The system comprises of: a core consists of the drug, rate-controlling polymer (forming hydrogel) and other excipients with pH independent coat surrounding core, comprising of water soluble and insoluble polymer and a film coat over it. Upon ingestion outer film coat dissolves exposing the coated tablet to the gastric fluids. Once the water soluble polymer from coat gets dissolved, pores are formed which allow penetration of fluid inside the membrane leading to hydration of core-forming hydrogel. Drug release occurs via slow diffusion out of the gel layer and subsequent gel erosion.
PURPOSE:To provide a remedy for autoimmune diseases, containing a suppressing factor (MNSF) acting antigen-nonspecifically to the production of antibody and giving a satisfactory result. CONSTITUTION:The objective agent contains, as an active component, a polypeptide MNSF having the following biological and physico-chemical properties. (i) Acting antigen-nonspecifically to the production of antibody and suppressing the production. (ii) Resistant to inactivation by 2-mercaptoethanol. (iii) Inactivated at 2 pH. (iv) Inactivated by trypsin treatment. The MNSF can be produced by fusing a BALB/C mouse spleen cell stimulated with concanavalin A and an AKR thymoma cell (SW5147) to obtain E17 cell capable of producing MNSF and culturing the E17 cell in a serum-free medium or a conventional medium. As an alternative method, the E17 cell is infused into the abdominal cavity of an (AKR/BALB/C) F1 mouse and the ascites of the mouse is subjected to hydroxyapatite chromatography.
A control group will be included in study design consisting of 7 schools selected randomly from 7 comparable yet adjacent Upazilas not slated for inclusion in the feeding programme. Use of a control group will enable later evaluations to attribute possible improvements in key impact/outcome variables to the intervention itself. An equal number of boys and girls will be selected from each class to enable gender analysis. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.No intervention had given in this group.
The invention relates to conjugates of saturated aliphatic chain alcohol, dexamethasone, and His-Gly-Glu, preparation, a nano structure, and applications thereof. The invention discloses 6 saturated aliphatic chain alcohol modified dexamethasone-His-Gly-Glu conjugates represented by the formula 10 a-f, wherein in the formula the n represents 7, 9, 11, 13, 15, or 17. The invention also discloses a preparation method, a nano structure, immunity inhibition activity, inflammation inhibition activity, and pain relieving activity of the conjugates. The invention also finds that the conjugates do not have any side effect leading to osteoporosis. The researches on the inhibition effect of the conjugates on splenic lymphocyte mitogen proliferation reactions and the survival time after mouse retroauricular cardiac muscle transplant show that the conjugates have an excellent immunity inhibition effect. The researches on the effect of the conjugates on the swelling degree of mouse ears which are inflamed due to xylene show that the conjugates have an excellent anti-inflammation effect. The researches on the effect of the conjugates on mouse heat radiation tail flick time show that the conjugates have an excellent pain-relieving effect. The researches on the effect of the conjugates on the mouse thigh bones show that the conjugates cannot cause osteoporosis. So the conjugates have a wide application prospect in the preparation of immunity inhibition drugs.
The invention relates to the field of traditional Chinese medicines, and particularly relates to a wheat fiber powder preparation used for treating ulcerative colitis and irritable bowel syndrome, and a preparation method and use thereof. The wheat fiber powder preparation includes the following raw material medicines in parts by weight: 4-7 parts of malt fiber, 4-5 parts of Poria cocos and 4-5 parts of Chinese yam. The invention further provides a preparation method and use of the wheat fiber powder preparation. Wheat fiber powder has an exact curative effect of treating the ulcerative colitis and the irritable bowel syndrome. The wheat fiber powder preparation has good effects of regulating intestinal bacteria, treating the irritable bowel syndrome and the ulcerative colitis, and the like. Medicinal materials used by the wheat fiber powder preparation provided by the invention are usually long-term edible medicine and food dual-purpose materials, so that the wheat fiber powder preparation is low in cost and free of any toxic or side effect, and has a very obvious effect of perfecting the intestinal bacteria.
Intake of carbohydrate-rich foods transiently increases blood glucose levels (known as postprandial glycaemia). Repeated high postprandial glucose responses are evidenced to dysregulate functional proteins, oxidative stress and pancreatic beta cell function; thus increasing the risk of diabetes and cardiovascular disease. Accordingly, meals that elicit a reduced, or more gradual, rise in blood glucose levels are desirable. Fruit polyphenols may help to limit the glucose excursion following a high carbohydrate meal. Previous research by our group has demonstrated that blackcurrant polyphenols significantly inhibited the average incremental area under the curve (T+0 to +30 min) of plasma glucose. Possible mechanisms include inhibition of intestinal enzymes and inhibition of intestinal glucose absorption by decreasing Sodium-glucose linked transporter 1 (SGLT-1) / Glucose transporter 2 (GLUT-2) glucose transporter activity. In vitro data suggests that citrus polyphenols may impact on carbohydrate metabolism by binding to starch molecules, however, effects on postprandial glycaemia are not yet known. Blackcurrants and citrus fruits have distinct polyphenol profiles and may therefore act on glucose homeostasis via different mechanisms. Blackcurrants are rich in anthocyanins and flavanols, whereas citrus fruits are rich in flavanones, hesperetin and naringenin. Theoretically, combining blackcurrant with citrus extracts may have synergistic effects.

The aim of this study is to investigate the effects of blackcurrant polyphenol extracts and citrus polyphenol extracts (and their combination), on postprandial glycaemia, insulinaemia and gastrointestinal hormone concentrations following a mixed carbohydrate test meal. It is hypothesised that blackcurrant and citrus extracts alone will inhibit glycaemia compared to placebo, a combination of the two will have a greater effect.

Study design: A randomised, controlled, double-blind, cross-over study will be conducted. Subjects will consume different drinks at 4 separate study visits. Drinks will contain either: blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose), blackcurrant and citrus extract (low dose + low dose), or placebo (no polyphenols). The study will utilise an incomplete block design. Subjects will consume the placebo drink and 3 out of 4 of the polyphenol-containing drinks during the study. At least a 7-day wash-out period will be required between study days. Baseline (fasted) blood samples will be taken in duplicate at T-10 min and T-5 min before consuming the test drink (T+0 min). Immediately following consumption of the drink, a mixed carbohydrate test meal will be consumed. Further blood samples will be collected at 10 min intervals for the first 30 min and then every 15 min until T+90 min and at T+120 min. Blood samples will be analysed for plasma glucose, insulin, glucose-dependent insulinotropic peptide (GIP), glucagon-like peptide 1 (GLP-1), peptide YY (PYY), C-peptide and nonesterified fatty acids (NEFA).
<P>PROBLEM TO BE SOLVED: To provide a non-natural type new disaccharide, in which new bioactivity and function can be expected, having galactose at the non-reducing terminal, and a composition containing the new disaccharide and to provide a method for producing the composition.  <P>SOLUTION: The disaccharide represented by formula (1) is obtained by dissolving α-bonded galactooligosaccharide or its derivative in which one or a plurality of galactoses are bonded in α pattern to a non-reducing terminal, a glucosamine salt or N-acetylglucosamine into a buffer solution or water and making α-galactosidase act on the solution. It is preferable to use melibiose or raffinose or its hydrate as the α-bonded galactooligosaccharide or its derivative. It is preferable to use glucosamine hydrochloride as the glucosamine salt. The disaccharide can be utilized as a raw material for foods, medicines, cosmetics, etc.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
In this randomized, Phase 3, double-blind, placebo-controlled study, patients will be randomized 2:1 to receive either a combination of pazopanib plus abexinostat or pazopanib plus placebo. At the time of disease progression, patient treatment assignment will be unblinded, and those patients randomized to the pazopanib plus placebo treatment arm will have the option of crossing over to receive treatment with a combination of pazopanib plus abexinostat. After providing written informed consent, patients will be screened for study eligibility within 28 days before their first dose of study drug. After screening assessments, patients who are eligible for inclusion in the study will be randomized and receive their first dose of study drug on Cycle 1 Day 1 (C1D1), within 7 days of randomization. A treatment cycle is 28 days in length. Patients may continue to receive study drug until any of the following events: the development of IRC-verified radiographic progression as assessed by RECIST version 1.1, clinical disease progression, unacceptable toxicity, another discontinuation criterion is met, withdrawal of consent, or closure of the study by the sponsor. No maximum duration of therapy has been set.
Lung cancer patients will be treated for four 3-week cycles (12 weeks) in the absence of progressive disease, unacceptable toxicity, or withdrawal of patient consent. Up to two additional cycles may be administered at the discretion of the treating physician. If at treatment withdrawal the disease has responded or is stable, the patient will continue to be followed for efficacy (i.e. until progressive disease)at 8 week intervals. Following the diagnosis of progressive disease, patients will be followed every two months for survival.
An image-type meal selling price and calorie evaluation system and method thereof are disclosed. The weight sensing unit is used for sensing the actual weight value of the meal. The image capturing unit is used for capturing the image of the meal. The image processing unit performs an image processing procedure on the image of the meal to obtain the processed image. The cloud computing unit performs an image recognition process on the processed image to obtain the food classification result and food location of the meal; performs an identification calculation process to calculate the identification result comprising the identification weight value of the meal, the price corresponding to the meal and the calorie value corresponding to the meal; and perform a comparison procedure to compare whether the actual weight value and the identification weight value are matched, and if yes, the cloud computing unit will transmit the display signal including the recognition result. The display unit is used for displaying the recognition result of the meal according to the display signal.